深静脉血栓形成患者血液中的纤溶酶原激活物抑制剂（PA抑制剂）活性 - Suppr | 超能文献

Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.

作者信息

Paramo J A, de Boer A, Colucci M, Jonker J J, Collen D

出版信息

Thromb Haemost. 1985 Oct 30;54(3):725.

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.深静脉血栓形成患者血液中的纤溶酶原激活物抑制剂（PA抑制剂）活性

Thromb Haemost. 1985 Oct 30;54(3):725.

2

Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.组织型纤溶酶原激活物及其快速作用抑制剂血浆水平的术后变化——与深静脉血栓形成的关系及预防的影响

Thromb Haemost. 1985 Oct 30;54(3):713-6.

3

[Fibrinolytic therapy--plasminogen activator inhibitors].[纤维蛋白溶解疗法——纤溶酶原激活物抑制剂]

Vasa Suppl. 1988;26:103-6.

4

Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood.血小板纤溶酶原激活物抑制剂：人血液中两种不同类型的内皮细胞纤溶酶原激活物抑制剂池。

Thromb Haemost. 1986 Jun 30;55(3):325-9.

5

Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator.人血浆中的组织型纤溶酶原激活物抑制剂：一种功能检测系统的开发及一种相对分子质量为50,000的抗激活剂的相关性证明

J Lab Clin Med. 1985 Jun;105(6):718-24.

6

[Anti-activator inhibitors of plasminogen].[纤溶酶原的抗激活剂抑制剂]

Ann Biol Clin (Paris). 1987;45(2):202-6.

7

Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation.肝移植过程中纤溶酶原激活物和纤溶酶原激活物抑制剂水平的变化。

Transplant Proc. 1989 Jun;21(3):3540-1.

8

The role of the fibrinolytic system in deep vein thrombosis.纤维蛋白溶解系统在深静脉血栓形成中的作用。

J Lab Clin Med. 1985 Feb;105(2):265-70.

9

Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture.纤溶酶原激活物抑制剂1抗原的血浆测定必须在采集于抗血小板/抗凝剂混合物的血液中进行。

Thromb Haemost. 1987 Dec 18;58(4):1096.

10

[Changes in plasma tissue plasminogen activator and plasminogen activator inhibitor in acute myocardial infarction and its clinical significance].[急性心肌梗死患者血浆组织型纤溶酶原激活物及纤溶酶原激活物抑制剂的变化及其临床意义]

Zhonghua Xin Xue Guan Bing Za Zhi. 1988 Aug;16(4):214-6, 254.

引用本文的文献

1

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory.新型冠状病毒肺炎相关血栓形成风险的管理：止血实验室指南

Thromb J. 2020 Sep 7;18:17. doi: 10.1186/s12959-020-00230-1. eCollection 2020.

2

Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue.1型纤溶酶原激活物抑制剂信使核糖核酸和蛋白在小鼠肾组织中的细胞定位

Am J Pathol. 1993 Jan;142(1):59-70.

3

Postoperative changes in plasma tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.血浆组织型纤溶酶原激活物及1型纤溶酶原激活物抑制剂的术后变化

Surg Today. 1994;24(12):1039-43. doi: 10.1007/BF01367453.